John Shimkus: “Do you want 10 new drugs, 30 new drugs on the market, 100 new drugs on the market or zero? H.R. 3 removes research and…”

“Do you want 10 new drugs, 30 new drugs on the market, 100 new drugs on the market or zero? H.R. 3 removes research and development investments, which will hinder innovation. Innovation doesn't always mean higher cost. Take hepatitis C, which lowers, reduces healthcare costs in the long run. Technology and innovation have always had the potential to reduce the time and costs of identifying and developing new therapies, which lower the cost of drugs. Incorporation of innovative genomic analysis means drug developers can reduce the amount of guesswork in identifying candidate molecules for further research. This same technology is being used by drug manufacturers today to help streamline and expedite the process of conducting trials. And investments in precision medicine will mean that you don't prescribe drugs that will not work or, in some cases, make people sicker. That is why I support H.R. 19, the Lower Costs, More Cures Act, which is composed entirely of bipartisan provisions and could become law right now.”